LifeArc, previously MRC Technology, set to transform the medical research landscape
Investment will focus on new innovations in therapeutics for neurodegeneration, antibiotic resistance, cancer and respiratory diseases.
LifeArc, the UK medical research charity previously known as MRC Technology1, has announced ambitious plans to improve the lives of patients suffering from diseases that present the greatest challenges to medical research. By investing up to £500 million over the next 5 years, LifeArc will seek to generate, fund and champion innovations in antimicrobials, neuroscience, personalised oncology and respiratory medicine.
The charity will build on its successful model of collaboration by setting up ‘Communities for Impact’. These networks will bring together the best partners to drive medical innovation in specific therapeutic and diagnostic areas. LifeArc’s work has already helped to develop treatments for patients suffering from cancer, rheumatoid arthritis, multiple sclerosis and Crohn’s disease, as well as an improved test for antibiotic resistance.
“Today is an important landmark in our history. LifeArc is a new name for an organisation that already has an impressive track record of pioneering new ways to turn the best science into patient treatments. The name LifeArc better reflects what we achieve in being the arc or bridge between great science and its application to help patients,” said Dr Dave Tapolczay, CEO, LifeArc.
LifeArc has also established two new funds for the progression of medical science and these are worth a combined £30 million over 4 years. The Philanthropic Fund will provide grants to support academic research funded by other medical research charities and organisations, while the Seed Fund will invest in early stage therapeutics and biological research.
“The funds build on our history of identifying and supporting early-stage scientific discoveries and will form part of the overall life science funding ecosystem to ensure a continuous pipeline of new treatments and diagnostics become available to patients,” Dr John Stageman, Chairman of LifeArc, added.
To accommodate the increase in new projects it progresses through its labs, LifeArc recently moved into state-of-the-art facilities in Stevenage and Edinburgh. The Stevenage site hosts around 80 scientists working on antibody and small molecule research, while £10 million is being invested to create a centre of excellence for diagnostic development in Edinburgh.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.